Wall Street brokerages expect that Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) will post earnings per share of ($0.62) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aquinox Pharmaceuticals’ earnings. Aquinox Pharmaceuticals reported earnings per share of ($0.46) in the same quarter last year, which suggests a negative year over year growth rate of 34.8%. The business is expected to issue its next quarterly earnings results on Wednesday, November 8th.
On average, analysts expect that Aquinox Pharmaceuticals will report full-year earnings of ($2.29) per share for the current year, with EPS estimates ranging from ($2.36) to ($2.21). For the next year, analysts forecast that the company will report earnings of ($2.38) per share, with EPS estimates ranging from ($2.40) to ($2.35). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Aquinox Pharmaceuticals.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.59).
AQXP has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. BidaskClub downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $22.25.
Several hedge funds and other institutional investors have recently bought and sold shares of AQXP. Nexthera Capital LP acquired a new stake in shares of Aquinox Pharmaceuticals in the second quarter valued at approximately $1,276,000. Sphera Funds Management LTD. acquired a new stake in shares of Aquinox Pharmaceuticals in the second quarter valued at approximately $874,000. Vanguard Group Inc. raised its holdings in shares of Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after purchasing an additional 17,455 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after purchasing an additional 11,035 shares during the last quarter. Finally, Investment Centers of America Inc. acquired a new stake in shares of Aquinox Pharmaceuticals in the first quarter valued at approximately $172,000. Institutional investors own 95.15% of the company’s stock.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 4.18% on Wednesday, reaching $13.31. 25,504 shares of the company were exchanged. The stock’s market capitalization is $312.31 million. Aquinox Pharmaceuticals has a 12 month low of $9.83 and a 12 month high of $19.97. The stock has a 50 day moving average price of $14.17 and a 200-day moving average price of $14.35.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/10/18/zacks-brokerages-anticipate-aquinox-pharmaceuticals-inc-aqxp-to-announce-0-62-eps.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Aquinox Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aquinox Pharmaceuticals Inc. and related companies.